Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Toxicity Conditioning for Pediatric Stem Cell Transplant
NCT00301834Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Jan 2005
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab, fludarabine, busulfan in Amegakaryocytic Thrombocytopenia (CAMT), Diamond-Blackfan anemia (DBA), leukemia, myelodysplastic syndrome (MDS), severe congenital neutropenia (SCN), sponsored by University of California, San Francisco. Started Jan 2005; status: completed.
02
Drugs
alemtuzumabfludarabinebusulfan
03
Conditions
Amegakaryocytic Thrombocytopenia (CAMT)Diamond-Blackfan anemia (DBA)leukemiamyelodysplastic syndrome (MDS)severe congenital neutropenia (SCN)
Beyond the preview
Go deeper on NCT00301834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00301834.